Blog
RSS FeedPosted by Michael Wonder on 01 Apr 2023
Outcome statement - February 2023 DUSC meeting
31 March 2023 - The outcome statement from the February 2023 DUSC meeting is now available. ...
Posted by Michael Wonder on 24 Feb 2023
Recommendations made out of session by the PBAC November 2022 and March 2023 meetings
24 February 2023 - Recommendations made out of session by the PBAC between its November 2022 and March 2023 meetings are ...
Posted by Michael Wonder on 27 Jan 2023
Recommendations made by the PBAC – December 2022 intracycle meeting
27 January 2023 - Recommendations made by the PBAC in December 2022 relating to the listing of drugs on the PBS ...
Posted by Michael Wonder on 22 Dec 2022
Final report for the post-market review of medicines for smoking cessation and review outcomes
22 December 2022 - The final report for the post-market review of medicines for smoking cessation is now available. The ...
Posted by Michael Wonder on 16 Dec 2022
Recommendations made by the PBAC – November 2022
16 December 2022 - The outcomes from the November 2022 PBAC meeting are now available. ...
Posted by Michael Wonder on 24 Nov 2022
Outcome in relation to discussion of COVID-19 oral treatments – November 2022 PBAC meeting
24 November 2022 - A PBAC outcome in relation to discussion of COVID-19 oral treatments at the November 2022 meeting has ...
Posted by Michael Wonder on 03 Nov 2022
Outcome statement - September 2022 DUSC meeting
3 November 2022 - The outcome statement from the September 2022 DUSC meeting is now available. ...
Posted by Michael Wonder on 14 Oct 2022
Outcomes from the September 2022 PBAC intracycle meeting
14 October 2022 - The recommendations made by the PBAC in September 2022 relating to the listing of medicines on ...
Posted by Michael Wonder on 19 Aug 2022
Recommendations made by the PBAC - July 2022
19 August 2022 - The recommendations from the July 2022 PBAC meeting are now available. ...
Posted by Michael Wonder on 11 Jul 2022
Drug Utilisation SubCommittee outcome statement
8 July 2022 - The outcome statement from the June 2022 DUSC meeting is now available. ...
Posted by Michael Wonder on 10 Jul 2022
PBAC recommendation for amendments to COVID-19 oral treatment restrictions
10 July 2022 - The PBAC recommended changes to the PBS eligibility criteria for both molnupiravir (Lagevrio) and nirmatrelvir and ritonavir ...
Posted by Michael Wonder on 17 Jun 2022
Outcomes of the May 2022 PBAC intracycle meeting
17 June 2022 - The outcomes from the May 2022 PBAC meeting are now available. ...
Posted by Michael Wonder on 05 May 2022
Insights from the March 2022 PBAC meeting (part 4)
5 May 2022 - The apparent high recommendation rate for the March 2022 meeting does have some downsides. ...
Posted by Michael Wonder on 28 Apr 2022
Insights from the March 2022 PBAC meeting (part 3)
29 April 2022 - Wegovy was the first discrete medicine to have a stakeholder meeting before its consideration by the ...
Posted by Michael Wonder on 27 Apr 2022
Insights from the March 2022 PBAC meeting (part 2)
28 April 2022 The rejection of dostarlimab should not come as a surprise, the rejection of sotorsaib less so. ...